Sphere-9 PAF China Study

A trial with no phase registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 180 participants.

Also called NCT07789925

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 180 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07789925
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT07789925. Allocation not applicable; no masking; primary purpose treatment. Start 2026-09-02 (anticipated); primary completion 2028-04 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Sphere-9 PAF China Study
Condition
Paroxysmal Atrial Fibrillation (PAF)
Intervention (Device)
Catheter ablation using Sphere-9™ Catheter and Affera™ Integrated Mapping and Ablation System
Lead sponsor
Medtronic Cardiac Ablation Solutions (class: industry)

Record details

Record id
cardio:ct-nct07789925
Content hash
b7a8e417b953b3de9c8b8097b5c380d0bbae7331a036d0011a896d9f7c50e33b